{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:19:21Z","timestamp":1780607961623,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/tpj.2016.26","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T10:03:03Z","timestamp":1461060183000},"page":"372-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients"],"prefix":"10.1038","volume":"17","author":[{"given":"N","family":"Ben Fredj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Gam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kerkni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Chaabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Chadly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Boughattas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Aouam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"key":"BFtpj201626_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935\u2013952.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFtpj201626_CR2","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.3748\/wjg.v13.45.6003","volume":"13","author":"N Higuchi","year":"2007","unstructured":"Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y et al. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 2007; 13: 6003\u20136008.","journal-title":"World J Gastroenterol"},{"key":"BFtpj201626_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.tube.2007.05.012","volume":"87","author":"HJ Cho","year":"2007","unstructured":"Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis 2007; 87: 551\u2013556.","journal-title":"Tuberculosis"},{"key":"BFtpj201626_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00228-008-0484-8","volume":"64","author":"LG Possuelo","year":"2008","unstructured":"Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008; 64: 673\u2013681.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201626_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/jhep.2002.32102","volume":"35","author":"YS Huang","year":"2002","unstructured":"Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY et al. Polymorphism of the N- acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883\u2013889.","journal-title":"Hepatology"},{"key":"BFtpj201626_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00228-006-0111-5","volume":"62","author":"N Vuilleumier","year":"2006","unstructured":"Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62: 423\u2013429.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201626_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cpt197518170","volume":"18","author":"JR Mitchell","year":"1975","unstructured":"Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975; 18: 70\u201379.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201626_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00008571-200104000-00004","volume":"11","author":"AJ Fretland","year":"2001","unstructured":"Fretland AJ, Leff MA, Doll MA, Hein DW . Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Phamacogenetics 2001; 11: 207\u2013215.","journal-title":"Phamacogenetics"},{"key":"BFtpj201626_CR9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/carcin\/bgm085","volume":"28","author":"Y Zang","year":"2007","unstructured":"Zang Y, Doll MA, Zhao S, States JC, Hein DW . Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 2007; 28: 1665\u20131671.","journal-title":"Carcinogenesis"},{"key":"BFtpj201626_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/10937400903158383","volume":"12","author":"K Walker","year":"2009","unstructured":"Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B . Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev 2009; 12: 440\u2013472.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"BFtpj201626_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.meegid.2014.01.034","volume":"24","author":"YJ Sheng","year":"2014","unstructured":"Sheng YJ, Wu G, He HY, Chen W, Zou YS, Li Q et al. The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis. Infect Genet Evol 2014; 24: 34\u201340.","journal-title":"Infect Genet Evol"},{"key":"BFtpj201626_CR12","first-page":"256","volume":"4","author":"M Ohno","year":"2000","unstructured":"Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4: 256\u2013261.","journal-title":"Int J Tuberc Lung Dis"},{"key":"BFtpj201626_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1248\/bpb.24.544","volume":"24","author":"T Kita","year":"2001","unstructured":"Kita T, Tanigawara Y, Chikazawa S, Hatanaka H, Sakaeda T, Komada F et al. N-acetyltransferase 2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull 2001; 24: 544\u2013549.","journal-title":"Biol Pharm Bull"},{"key":"BFtpj201626_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2133\/dmpk.17.357","volume":"17","author":"M Hiratsuka","year":"2002","unstructured":"Hiratsuka M, Kishikawa Y, Takekuma Y, Matsuura M, Narahara K, Inoue T et al. Genotyping the N-acetyltransferase 2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 2002; 17: 357\u2013362.","journal-title":"Drug Metab Pharmacokinet"},{"key":"BFtpj201626_CR15","first-page":"43","volume":"39","author":"J Singh","year":"1995","unstructured":"Singh J, Garg PK, Thakur VS, Tandon RK . Antitubercular treatment induced hepatotoxicity: does acetylator status matter? Indian J Physiol Pharmacol 1995; 39: 43\u201346.","journal-title":"Indian J Physiol Pharmacol"},{"key":"BFtpj201626_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1440-1681.2012.05713.x","volume":"39","author":"HR An","year":"2012","unstructured":"An HR, Wu XQ, Wang ZY, Zhang J, Liang Y . NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 2012; 39: 535\u2013543.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFtpj201626_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1440-1746.2010.06355.x","volume":"26","author":"PD Bose","year":"2011","unstructured":"Bose PD, Sarm MP, Medhi S, Das BC, Husain S, Kar P et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26: 312\u2013318.","journal-title":"J Gastroenterol Hepatol"},{"key":"BFtpj201626_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1053\/jhep.2003.50144","volume":"37","author":"YS Huang","year":"2003","unstructured":"Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924\u2013930.","journal-title":"Hepatology"},{"key":"BFtpj201626_CR19","first-page":"622","volume":"14","author":"SW Lee","year":"2010","unstructured":"Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS . NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis druginduced hepatitis. Int J Tuberc Lung Dis 2010; 14: 622\u2013626.","journal-title":"Int J Tuberc Lung Dis"},{"key":"BFtpj201626_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1177\/147323001003800324","volume":"38","author":"T Wang","year":"2010","unstructured":"Wang T, Yu HT, Wang W, Pan YY, He LX, Wang ZY . Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. J Int Med Res 2010; 38: 977\u2013986.","journal-title":"J Int Med Res"},{"key":"BFtpj201626_CR21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-2710.2012.01334.x","volume":"37","author":"SW Tang","year":"2012","unstructured":"Tang SW, Lv XZ, Zhang Y, Wu SS, Yang ZR, Xia YY et al. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study. J Clin Pharm Ther 2012; 37: 588\u2013593.","journal-title":"J Clin Pharm Ther"},{"key":"BFtpj201626_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/jgh.12069","volume":"28","author":"JG Chamorro","year":"2013","unstructured":"Chamorro JG, Castagnino JP, Musella RM, Nogueras M, Aranda FM, Fr\u00edas A . Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol 2013; 28: 323\u2013328.","journal-title":"J Gastroenterol Hepatol"},{"key":"BFtpj201626_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.5588\/ijtld.12.0645","volume":"17","author":"NP Santos","year":"2013","unstructured":"Santos NP, Callegari-Jacques SM, Ribeiro Dos Santos AK, Silva CA, Vallinoto AC, Fernandes DC et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis 2013; 17: 499\u2013504.","journal-title":"Int J Tuberc Lung Dis"},{"key":"BFtpj201626_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","volume":"11","author":"C Benichou","year":"1990","unstructured":"Benichou C . Criteria for drug-induced liver disorder: report of an international consensus meeting. J Hepatol 1990; 11: 272\u2013276.","journal-title":"J Hepatol"},{"key":"BFtpj201626_CR25","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"Miller Sa","year":"1988","unstructured":"Sa Miller, Dd Dykes, Hf Polesky . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.","journal-title":"Nucleic Acids Res"},{"key":"BFtpj201626_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00008571-199408000-00002","volume":"4","author":"EA Stephens","year":"1994","unstructured":"Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW et al. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994; 4: 185\u2013192.","journal-title":"Pharmacogenetics"},{"key":"BFtpj201626_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0304-3835(99)00192-5","volume":"143","author":"SA Salama","year":"1999","unstructured":"Salama SA, Sierra-Torres CH, Oh HY, Hamada FA, Au WW . A multiplex- PCR\/RFLP procedure for simultaneous CYP2E1, mEH and GSTM1 genotyping. Cancer Lett 1999; 143: 51\u201356.","journal-title":"Cancer Lett"},{"key":"BFtpj201626_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1440-1746.2010.06355.x","volume":"26","author":"DB Purabi","year":"2011","unstructured":"Purabi DB, Manash PS, Subhash M, Bhudev CD, Syed AH, Premashis K . Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment induced hepatitis. Gastroenterol Hepatol 2011; 26: 312\u2013318.","journal-title":"Gastroenterol Hepatol"},{"key":"BFtpj201626_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","volume":"23","author":"A Tostmann","year":"2008","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R . Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192\u2013202.","journal-title":"J Gastroenterol Hepatol"},{"key":"BFtpj201626_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3346\/jkms.2015.30.2.167","volume":"30","author":"I Jeong","year":"2015","unstructured":"Jeong I, Park JS, Cho YJ, Yoon HI, Song J, Lee CT et al. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci 2015; 30: 167\u2013172.","journal-title":"J Korean Med Sci"},{"key":"BFtpj201626_CR31","first-page":"58","volume":"129","author":"P Gurumurthy","year":"1984","unstructured":"Gurumurthy P, Krishnamurthy MS, Nazareth O, Parthasarathy R, Sarma GR . Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129: 58\u201361.","journal-title":"Am Rev Respir Dis"},{"key":"BFtpj201626_CR32","first-page":"753","volume":"1","author":"JN Vivien","year":"1973","unstructured":"Vivien JN, Thibier R, Lepeuple A . La pharmacocin\u00e9tique de l\u2019isoniazide dans la race blanche. Rev Fr Mal Resp 1973; 1: 753\u2013772.","journal-title":"Rev Fr Mal Resp"},{"key":"BFtpj201626_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0163-7258(89)90036-3","volume":"42","author":"DA Evans","year":"1989","unstructured":"Evans DA . N-Acetyltransferase. Pharmacol Ther 1989; 42: 157\u2013234.","journal-title":"Pharmacol Ther"},{"key":"BFtpj201626_CR34","first-page":"1239","volume":"10","author":"S Garte","year":"2001","unstructured":"Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10: 1239\u20131248.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFtpj201626_CR35","first-page":"9","volume":"5","author":"MO Tanira","year":"2003","unstructured":"Tanira MO, Simsek M, Al Balushi K, Al Lawatia K, Al Barawani H, Bayoumi RA . Distribution of arylamine N-acetyltransferase 2 (nat2) genotypes among Omanis. J Sci Res Med Sci 2003; 5: 9\u201314.","journal-title":"J Sci Res Med Sci"},{"key":"BFtpj201626_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00008571-199406000-00003","volume":"4","author":"HJ Lin","year":"1994","unstructured":"Lin HJ, Han CY, Lin BK, Hardy S . Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4: 125\u2013134.","journal-title":"Pharmacogenetics"},{"key":"BFtpj201626_CR37","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1046\/j.1365-2125.2003.01786.x","volume":"55","author":"SI Hamdy","year":"2003","unstructured":"Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol 2003; 55: 560\u2013569.","journal-title":"Br J Clin Pharmacol"},{"key":"BFtpj201626_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2156-9-21","volume":"9","author":"A Sabbagh","year":"2008","unstructured":"Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES . Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet 2008; 9: 21.","journal-title":"BMC Genet"},{"key":"BFtpj201626_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12863-014-0156-x","volume":"15","author":"S Guaoua","year":"2014","unstructured":"Guaoua S, Ratbi I, Laarabi FZ, Elalaoui SC, Jaouad IC, Barkat A et al. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population. BMC Genet 2014; 15: 156.","journal-title":"BMC Genet"},{"key":"BFtpj201626_CR40","first-page":"2068","volume":"6","author":"SC Kunak","year":"2012","unstructured":"Kunak SC, Ada AO, Karacaoglan V, Soydas E, Bilgen S, Iscan M . Drug\/xenobiotic metabolizing enzyme polymorphisms in a Turkish population. African J Pharm Pharmacol 2012; 6: 2068\u20132074.","journal-title":"African J Pharm Pharmacol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201626","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/tpj.2016.26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:18:35Z","timestamp":1647947915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFtpj201626"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2016.26","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,19]]},"assertion":[{"value":"1 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}